Ube, Japan

Hiroyuki Ota

This inventor holds 1 USPTO granted patent. Top assignee: Ube Industries, Inc.. Active years: 2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroyuki Ota. Retrieved from https://idiyas.com/inventor/hiroyuki-ota-efvrpcdq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroyuki Ota: Inventor in Chemical Process Innovation.

Introduction

Hiroyuki Ota is an inventor associated with Ube, Japan, and Ube Industries, Inc. His work includes a patented chemical process for producing pyrazole compounds and related intermediates.

Latest Patents

Ota is credited with 1 patent. His patent, “Process for Producing 3-Unsubstituted 5-Amino-4-Nitrosopyrazole Compound, and 2-Hydroxyimino-3-Oxopropionitrile, 3-Hydrazono-2-Hydroxyiminopropionitrile Compound, and Processes for Producing These,” describes a process for preparing a 3-unsubstituted-5-amino-4-nitrosopyrazole compound represented by formula (1). The patent also concerns related compounds and methods for producing them.

Career Highlights

Ota’s listed patent reflects work in chemical synthesis and process development. The invention focuses on preparing a specified pyrazole compound and associated chemical intermediates.

Collaborations

Masanori Sone and Masayoshi Oku are identified as Ota’s coworkers in connection with the information provided. The patent is associated with Ube Industries, Inc.

Conclusion

Hiroyuki Ota’s recorded contribution is a chemical-process patent concerning the production of a pyrazole compound and related intermediates, associated with Ube Industries, Inc.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…